Atara Biotherapeutics Files Q2 2024 10-Q

TL;DR

**ATARA 10-Q FILED: Q2 financials out, check common stock, warrants, and key agreements like HCRX & Fujifilm.**

AI Summary

Atara Biotherapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and results of operations, including details on its common stock, warrants, and various agreements like the HCRX Agreement and the Fujifilm Master Services and Supply Agreement. The filing also references its 2014 Equity Incentive Plan and Inducement Plan.

Why It Matters

This filing provides investors with an update on Atara's financial health and operational activities, crucial for understanding the company's current standing and future prospects in the biopharmaceutical sector.

Risk Assessment

Risk Level: medium — Biopharmaceutical companies often carry medium to high risk due to the inherent uncertainties in drug development, regulatory approvals, and market competition.

Key Numbers

• 2024-06-30 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is provided.)
• 2024-08-12 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• Atara Biotherapeutics, Inc. (company) — Filer of the 10-Q
• 2024-06-30 (date) — End of the reporting period
• 2024-08-12 (date) — Filing date of the 10-Q
• HCRX Agreement (contract) — Mentioned agreement
• Fujifilm Master Services and Supply Agreement (contract) — Mentioned agreement
• 2014 Equity Incentive Plan and Inducement Plan (plan) — Employee incentive plan

FAQ

Key Financial Figures

• $0.0001 — ch Registered Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Mar

Filing Documents

• atra-20240630.htm (10-Q) — 2292KB
• atra-ex10_1.htm (EX-10.1) — 31KB
• atra-ex10_2.htm (EX-10.2) — 42KB
• atra-ex31_1.htm (EX-31.1) — 14KB
• atra-ex31_2.htm (EX-31.2) — 14KB
• atra-ex32_1.htm (EX-32.1) — 10KB
• 0000950170-24-095533.txt ( ) — 8173KB
• atra-20240630.xsd (EX-101.SCH) — 1249KB
• atra-20240630_htm.xml (XML) — 1162KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) Condensed Consolidated Balance Sheets 6 Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) 7 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) 8 Condensed Consolidated Statements of Cash Flows 9 Notes to Condensed Consolidated Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 36 Item 4.

Controls and Procedures

Controls and Procedures 36 PART II. OTHER INFORMATION 37 Item 1.

Legal Proceedings

Legal Proceedings 37 Item 1A.

Risk Factors

Risk Factors 37 Item 5. Other Information 84 Item 6. Exhibits 85

Signatures

Signatures 86 2 NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements, which represent our intent, belief or current expectations, involve risks and uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "predict," "plan," "expect" or the negative or plural of these words or similar expressions. The forward-looking statements include, but are not limited to, statements about: our expectations regarding the timing of initiating clinical studies, opening client sites, enrolling clinical studies and reporting results of clinical studies for our programs, including our ATA3219 program; the likelihood and timing of regulatory submissions or related approvals for our product candidates, including the expectations about the timing of approvals for a biologics license application (BLA) for tab-cel for patients with Epstein-Barr virus with post-transplant lymphoproliferative disease (EBV+ PTLD); the potential indications for our product and product candidates; commercialization of tab-cel (Ebvallo in the United Kingdom (UK), the European Economic Area (EEA) and Switzerland) worldwide and our amended and restated Commercialization Agreement with Pierre Fabre Medicament, including potential milestone and royalty payments under the agreement (Ebvallo in the UK, the EEA and Switzerland subject to the Purchase and Sale Agreement with HCR Molag Fund, L.P.); our Purchase and Sale Agreement and related transactions with HCR Molag Fund, L.P.; our

View Full Filing

View this 10-Q filing on SEC EDGAR